



# NEWS RELEASE

## FOR IMMEDIATE RELEASE

### Contact:

Caton Lovett  
Pure Communications, Inc.  
(910) 232-7166

## Foundation Medicine to Present Data on Next-Generation Sequencing Approach to Cancer Genome Analysis at Several Upcoming Industry Conferences

**CAMBRIDGE, Mass. – June 22, 2011** – [Foundation Medicine, Inc.](#), a cancer diagnostics company that aims to bring comprehensive cancer genome analysis to routine care, today announced that members of the Foundation Medicine team will present data highlighting progress toward clinical application of the company’s next-generation sequencing (NGS)-based approach to comprehensive molecular analysis of tumors.

Michael J. Pellini, M.D., president and chief executive officer of Foundation Medicine commented, “We believe that our test promises a significant advance in cancer diagnostics. The ability to comprehensively capture relevant, actionable genomic information from small tissue specimens with one test will allow physicians to offer treatments tailored to each patient based on the molecular subtype of their cancer. These conferences provide us with a valuable opportunity to engage with our industry peers, and we look forward to sharing data supporting Foundation Medicine’s approach using NGS for comprehensive cancer genome analysis and the potential applications of our test in routine cancer care.”

The schedule for Foundation Medicine presentations is as follows:

- **Keystone Symposia Conference: Changing Landscape of the Cancer Genome in Boston, Mass.:** Doron Lipson, Ph.D., senior computational biologist at Foundation Medicine, will present a poster entitled “Applying NGS to cancer genomics for clinical decision making” at 12:30pm (EDT) on Wednesday, June 22, 2011, followed by a talk with the same title at 5:00 p.m. (EDT) on Friday, June 24, 2011.
- **The 3<sup>rd</sup> Worldwide Innovative Networking (WIN) Symposium in Personalized Cancer Medicine in Paris, France:** Gary Palmer, M.D., J.D., M.B.A., M.P.H., senior vice president, medical affairs and commercial development at Foundation Medicine, will present a poster entitled “Comprehensive mutation profiling by deep sequencing from fixed cancer tissues” on July 6, 2011.
- **HiTSeq 2011 Conference on High Throughput Sequencing Analysis and Algorithms in Vienna, Austria:** Dr. Lipson will give a talk entitled “An assembly-based algorithm

for sensitive detection of insertions and deletions in targeted resequencing data of clinical cancer specimens” at the conference which is taking place July 15-16, 2011.

- **American Association for Clinical Chemistry (AACC) Annual Meeting 2011 in Atlanta, Ga.:** John Curran, Ph.D., director, clinical laboratory at Foundation Medicine, will present a poster entitled “Exploratory study using comprehensive next-generation sequencing on DNA from FFPE tumor tissue comparing KRAS, EGFR and BRAF gene mutation results with reference laboratory genotyping assays” at 10:00 a.m. (EDT) on Tuesday, July 26, 2011.

### **About Foundation Medicine**

Foundation Medicine is dedicated to the development of a comprehensive diagnostic test that improves cancer care by helping physicians personalize treatment for their patients. Foundation Medicine’s laboratory test is being designed to accommodate a broad landscape of cancer genome information and a growing repertoire of more targeted treatments and clinical research opportunities. Foundation Medicine’s test will assist physicians to make prompt and informed determinations about the best cancer treatments and clinical trial options for each patient, taking into account each patient’s unique cancer-associated alterations alongside publicly available scientific and medical information. The company’s founding advisors are world leaders in genome technology, cancer biology and medical oncology; they, alongside clinicians, biotech and molecular diagnostics industry leaders, are working to harness emerging technologies to develop unparalleled tests that will identify and interpret an ever-growing set of actionable genomic alterations, truly enabling personalized cancer medicine. For more information, please visit the company’s website at [www.foundationmedicine.com](http://www.foundationmedicine.com).

###